Position in CGC
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$20,561
-$728 QoQ
Shares Held
21,666
+16.0% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in CGC Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Cetera Investment Advisers holds $48,125,230 across 32 Drug Manufacturers - Specialty & Generic names. CGC ranks #32 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
80,566 | $9,523,706 | |
| 2 | VTRS |
Viatris Inc
|
385,999 | $5,214,846 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
8,648 | $5,128,091 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
224,015 | $4,148,757 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
121,502 | $2,907,542 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
20,245 | $2,667,076 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
87,216 | $2,626,945 | |
| 8 | HLN |
Haleon plc
|
247,741 | $2,479,887 |
All Filings in CGC
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $20,561 | 21,666 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $21,289 | 18,675 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $39,097 | 26,779 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $37,860 | 31,033 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $45,804 | 50,335 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $114,137 | 41,656 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $322,048 | 66,815 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $365,160 | 56,614 | Shares | Sole | 2024-08-22 | |
| 2023-12-31 | $58,018 | 11,354 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||